Adam McIntyre

Mr. Adam McIntyre

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JDJacqueline S. Dron
Jacqueline S. Dron
JWJian Wang
Jian Wang
AMAdam McIntyre
Adam McIntyre
MIMichael A. Iacocca
Michael A. Iacocca
JRJohn F. Robinson
John F. Robinson
RHRobert Hegele
Robert Hegele
Background: In 2013, our laboratory designed a targeted sequencing panel, “LipidSeq”, to study the genetic determinants of dyslipidemia and metabolic disorders. Over the last 6 years, we have analyzed 3262 patient samples obtained from our own Lipid Genetics Clinic and international colleagues. Here, we highlight our findings and discuss research benefits and clinical implications of our panel. Methods: LipidSeq targets 69 genes and 185 single-nucleotide polymorphisms (SNPs) either causally related or associated with dyslipidemia and metabolic disorders. This design allows us to simultaneously evaluate monogenic—caused by rare single-nucleotide variants (SNVs) or copy-number variants (CNVs)—and polygenic forms of dyslipidemia. Polygenic determinants were assessed using three polygenic scores, one each for low-density lipoprotein cholesterol, triglyceride, and high-density lipoprotein cholesterol. Results: Among 3262 patient samples evaluated, the majority had hypertriglyceridemia (40.1%) and familial hypercholesterolemia (28.3%). Across all samples, we identified 24,931 unique SNVs, including 2205 rare variants predicted disruptive to protein function, and 77 unique CNVs. Considering our own 1466 clinic patients, LipidSeq results have helped in diagnosis and improving treatment options. Conclusions: Our LipidSeq design based on ontology of lipid disorders has enabled robust detection of variants underlying monogenic and polygenic dyslipidemias. In more than 50 publications related to LipidSeq, we have described novel variants, the polygenic nature of many dyslipidemias—some previously thought to be primarily monogenic—and have uncovered novel mechanisms of disease. We further demonstrate several tangible clinical benefits of its use.

1 January 2021 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
PGPraneet K. Gill
Praneet K. Gill
JDJacqueline S. Dron
Jacqueline S. Dron
ABAmanda J. Berberich
Amanda J. Berberich
JWJian Wang
Jian Wang
AMAdam McIntyre
Adam McIntyre
RHRobert Hegele
Robert Hegele
Combined hyperlipidemia (CHL) is a common disorder defined by concurrently elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. Despite decades of study, the genetic basis of CHL remains unclear. To characterize the genetic profiles of patients with CHL and compare them to those in patients with isolated hypercholesterolemia and isolated hypertriglyceridemia (HTG). DNA from 259, 379 and 124 patients with CHL, isolated hypercholesterolemia and isolated HTG, respectively, underwent targeted sequencing. We assessed: 1) rare variants disrupting canonical LDL-C or TG metabolism genes; and 2) two polygenic scores-for elevated LDL-C and TG-calculated using common trait-associated single-nucleotide polymorphisms (SNPs). Genetic profiles were compared against 1000 Genomes Project controls. Both CHL and isolated HTG patients had significantly increased odds of a high polygenic score for TG: 2.50 (95% confidence interval [CI] 1.61-3.88; P < 0.001) and 3.72 (95% CI 2.24-6.19; P < 0.001), respectively. CHL patients had neither a significant accumulation of rare variants for LDL-C or TG, nor a high polygenic score for LDL-C. In contrast, patients with isolated hypercholesterolemia had a 3.03-fold increased odds (95% CI 2.22-4.13; P < 0.001) of carrying rare variants associated with familial hypercholesterolemia, while patients with isolated HTG had a 2.78-fold increased odds (95% CI 1.27-6.10; P = 0.0136) of carrying rare variants associated with severe HTG. CHL is genetically similar to isolated HTG, a known polygenic trait. Both cohorts had a significant accumulation of common TG-raising variants. Elevated LDL-C levels in CHL are not associated with common or rare LDL-C-related genetic variants.

5 January 2025 in Genes
Verified
Journal Article
Open access
PDF file
SPShehan Dinuka Perera
Shehan Dinuka Perera
JWJian Wang
Jian Wang
AMAdam McIntyre
Adam McIntyre
RHRobert Hegele
Robert Hegele
Biallelic rare pathogenic loss-of-function (LOF) variants in lipoprotein lipase (LPL) cause familial chylomicronemia syndrome (FCS). Heterozygosity for these same variants is associated with a highly variable plasma triglyceride (TG) phenotype ranging from normal to severe hypertriglyceridemia (HTG), with longitudinal variation in phenotype severity seen often in a given carrier. Here, we provide an updated overview of genetic variation in LPL in the context of HTG, with a focus on disease-causing and/or disease-associated variants. We provide a curated list of 300 disease-causing variants discovered in LPL, as well as an exon-by-exon breakdown of the LPL gene and protein, highlighting the impact of variants and the various functional residues of domains of the LPL protein. We also provide a curated list of variants of unknown or uncertain significance, many of which may be upgraded to pathogenic/likely pathogenic classification should an additional case and/or segregation data be reported. Finally, we also review the association between benign/likely benign variants in LPL, many of which are common polymorphisms, and the TG phenotype.

1 January 2021 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
PGPraneet K. Gill
Praneet K. Gill
JDJacqueline S. Dron
Jacqueline S. Dron
ADAllison Dilliott
Allison Dilliott
AMAdam McIntyre
Adam McIntyre
HCHenian Cao
Henian Cao
RHRobert Hegele
Robert Hegele

1 November 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
JDJacqueline S. Dron
Jacqueline S. Dron
JWJian Wang
Jian Wang
AMAdam McIntyre
Adam McIntyre
HCHenian Cao
Henian Cao
JRJohn F. Robinson
John F. Robinson
RHRobert Hegele
Robert Hegele
Jacqueline S. Dron, Jian Wang, Adam D. McIntyre, Henian Cao, John F. Robinson, P. Barton Duell, Priya Manjoo, James Feng, Irina Movsesyan, Mary J. Malloy, Clive R. Pullinger, John P. Kane, Robert A. Hegele

1 March 2021 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
SGSamer Gawrieh
Samer Gawrieh
TLTiebing Liang
Tiebing Liang
AMAdam McIntyre
Adam McIntyre
RHRobert A. Hegele
Robert A. Hegele
NCNaga Chalasani
Naga Chalasani